First Time Loading...

Atossa Therapeutics Inc
NASDAQ:ATOS

Watchlist Manager
Atossa Therapeutics Inc Logo
Atossa Therapeutics Inc
NASDAQ:ATOS
Watchlist
Price: 1.52 USD -0.65%
Updated: May 3, 2024
Section:
 

Wall Street
Price Targets

ATOS Price Targets Summary
Atossa Therapeutics Inc

Wall Street analysts forecast ATOS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ATOS is 4.67 USD with a low forecast of 4.04 USD and a high forecast of 6.04 USD.

ATOS Lowest Forecast
Wall Street Target
4.04 USD
166% Upside
ATOS Average Forecast
Wall Street Target
4.67 USD
208% Upside
ATOS Highest Forecast
Wall Street Target
6.04 USD
297% Upside
Lowest
Price Target
4.04 USD
166% Upside
Average
Price Target
4.67 USD
208% Upside
Highest
Price Target
6.04 USD
297% Upside

ATOS Last Price Targets
Atossa Therapeutics Inc

The latest public price target was made on Sep 8, 2023 by Louise Chen from Cantor Fitzgerald , who expects ATOS stock to rise by 229% over the next 12 months. You can read more about this price target by viewing the article on Benzinga.

Analyst Price Target Date Article
Louise Chen
Cantor Fitzgerald
5 USD
Upside 229%
7 months ago
Sep 8, 2023
Breast Cancer-Focused Atossa Therapeutics Can Possibly Change Treatment Paradigm: Analyst
Benzinga
Louise Chen
Cantor Fitzgerald
Price Target 5 USD
Upside/Downside 229%
View Source
Atossa Therapeutics Inc Competitors:
Price Targets
4587
PeptiDream Inc
38% Upside
300639
Guangdong Hybribio Biotech Co Ltd
540% Upside
W
300142
Walvax Biotechnology Co Ltd
39% Upside
SPRY
ARS Pharmaceuticals Inc
105% Upside
4587
PeptiDream Inc
38% Upside
300639
Guangdong Hybribio Biotech Co Ltd
540% Upside
W
300142
Walvax Biotechnology Co Ltd
39% Upside
SPRY
ARS Pharmaceuticals Inc
105% Upside
ABOS
Acumen Pharmaceuticals Inc
268% Upside
S
6990
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
12% Upside
ARQT
Arcutis Biotherapeutics Inc
128% Upside
ANIK
Anika Therapeutics Inc
11% Upside

Revenue
Forecast

Revenue Estimate
Atossa Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Atossa Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-7%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Atossa Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-93%
Average Miss
What are analyst estimates?

See Also

Summary
ATOS intrinsic value, competitors valuation, and company profile.
DCF Valuation
ATOS stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ATOS stock valuation using valuation multiples.
Wall Street Estimates
ATOS price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ATOS stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ATOS's stock price target?
Price Target
4.67 USD

According to Wall Street analysts, the average 1-year price target for ATOS is 4.67 USD with a low forecast of 4.04 USD and a high forecast of 6.04 USD.

ALPHA SPREAD
Join more than 133,900+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.